Skip to content
Clinical Trials – home

Azienda Ospedaliera Santobono Pausilipon

Verified siteinfo

Italy Presidio Ospedaliero Santobono, Via Mario Fiore 6, 80129 Naples, Italy

  • 19 trials recruiting
  • Acute lymphocytic leukaemia · Acute myeloid leukaemia · Acute lymphocytic leukaemia recurrent
  • Adults and children

About Specializations

Azienda Ospedaliera Santobono Pausilipon in Naples, Italy specialises in clinical trials of conditions such as Acute lymphocytic leukaemia, Acute myeloid leukaemia, Acute lymphocytic leukaemia recurrent, B-cell type acute leukaemia, and other specialisations. This site conducts important research.

Main research areas of the site

Hematologic Malignancies and Leukemia Research

At Azienda Ospedaliera Santobono Pausilipon in Naples, a major focus is hemic and lymphatic diseases, especially pediatric acute lymphoblastic leukemia, acute myeloid leukemia, and relapsed or high-risk blood cancers. The trials are designed to improve survival, refine treatment strategies, and test newer immunotherapy and targeted approaches for children and adolescents.

  • Studies in acute lymphoblastic leukemia, including relapsed, refractory, and Philadelphia chromosome-positive disease
  • Research in acute myeloid leukemia, including genetic subtypes and treatment-resistant cases
  • Evaluation of immunotherapy, targeted therapy, and treatment intensification to improve outcomes
  • Work on hematopoietic stem cell transplantation and post-transplant relapse prevention

This program reflects a strong commitment to better disease control, safer treatment, and more personalized care for young patients with complex blood cancers.

Pediatric Solid Tumors and Neuro-oncology

Clinical research here also covers neoplasms of the brain and soft tissues, with studies in neuroblastoma, glioma, medulloblastoma, ependymoma, diffuse intrinsic pontine glioma, osteosarcoma, and Ewing sarcoma. These trials aim to improve tumor control, survival, and quality of life through better systemic therapy and radiation-based strategies.

  • Trials in high-risk neuroblastoma to strengthen treatment response and reduce relapse
  • Studies in brain tumors such as glioma, medulloblastoma, ependymoma, and DIPG
  • Research in Ewing sarcoma and osteosarcoma to compare treatment approaches and improve outcomes
  • Testing of targeted and immunotherapy options for difficult-to-treat pediatric tumors

The site’s oncology team is involved in studies that seek more effective treatment combinations while limiting long-term toxicity in children and young adults.

Skin Injury, Burns, and Reconstructive Care

A notable area of research at Azienda Ospedaliera Santobono Pausilipon involves skin and connective tissue diseases, especially severe burns and large skin defects in children and adults. These trials focus on improving wound closure, scar quality, and recovery after major skin injury.

  • Studies in deep partial and full-thickness burns
  • Research for large full-thickness skin defects in children and adults
  • Evaluation of new skin graft and wound repair approaches
  • Assessment of healing outcomes and reduction of scarring

This work aims to support better reconstructive care and faster recovery after severe tissue damage.

Rare Blood Disorders and Bleeding Conditions

The site also conducts trials in hemophilia and inherited bleeding disorders, within the broader field of hemic diseases. These studies are intended to improve bleeding control, safety, and day-to-day management for children with rare coagulation disorders.

  • Research in hemophilia A and severe inherited von Willebrand disease
  • Evaluation of treatments for non-surgical bleeding episodes
  • Studies of hemostatic efficacy and treatment tolerability in pediatric patients
  • Support for safer care in children with chronic bleeding risk

These trials contribute to more reliable bleeding prevention and improved quality of life for affected families.

Neuromuscular and Digestive System Research

Additional studies at the site address nervous system diseases and digestive system diseases, including generalized myasthenia gravis, gastrointestinal graft-versus-host disease, and bowel preparation in children. The purpose is to improve symptom control, treatment safety, and supportive care in complex pediatric conditions.

  • Trials in generalized myasthenia gravis to assess safety and long-term tolerability of newer treatments
  • Research in gastrointestinal aGvHD to help children after prior treatment failure
  • Studies on bowel cleansing for pediatric colonoscopy preparation
  • Supportive-care research aimed at improving comfort and treatment success

Together, these studies show a broad clinical research portfolio that extends beyond oncology into rare neurological and gastrointestinal care.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Presidio Ospedaliero Santobono, Via Mario Fiore 680129 NaplesItaly
Recruiting now
19 trials
Conditions studied
39
Partner status
Verified site

More sites in NaplesItaly

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

39 clinical trials

Treatment Study of Arsenic Trioxide, Tretinoin, and Gemtuzumab Ozogamicin for Children and Adolescents with Acute Promyelocytic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Arsenic Trioxide
  • Sponsor:Associazione Italiana Ematologia Oncologia Pediatrica

Study of Revumenib, Cytarabine, and Fludarabine in Children with Relapsed or Refractory Acute Myeloid Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Cytarabine
  • Sponsor:Pediatric Research International GmbH
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Ascorbic Acid
  • Sponsor:Norgine Limited

A Study of Atumelnant for Children with Congenital Adrenal Hyperplasia

Investigational
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Atumelnant
  • Sponsor:Crinetics Pharmaceuticals Inc.

Study of chemotherapy with blinatumomab and tyrosine kinase inhibitors in newly diagnosed children and young adults with Philadelphia chromosome positive B-cell acute lymphoblastic leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:Universita Degli Studi Di Milano Bicocca

Testing Stem Cell Transplant Methods and Medications Including Ruxolitinib and Blinatumomab for Children and Young Adults with Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:Ospedale Pediatrico Bambino Gesu

Study on the Effectiveness of Denosumab with Chemotherapy (Cisplatin, Methotrexate, Doxorubicin) for Patients with Metastatic Osteosarcoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Cisplatin
  • Sponsor:Associazione Italiana Ematologia Oncologia Pediatrica

Study of drug combination therapy for patients with recurrent and primary refractory Ewing Sarcoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Anhydrous Docetaxel
  • Sponsor:The University Of Birmingham

Thermal burn

Recruiting

Study on the Effectiveness of EHSG-KF Skin Graft for Patients with Deep Partial and Full-Thickness Burns

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bilayer Engineered Collagen Hydrogel-Based Skin Graft Composed Of Autologous Keratinocytes And Fibroblasts
  • Sponsor:Cutiss AG

Study Comparing Inotuzumab Ozogamicin to Drug Combination for Children with High-Risk Relapsed B-cell Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Crisantaspase
  • Sponsor:Pfizer Inc.
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Bortezomib
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Medulloblastoma

Recruiting

Study of drug combination therapy for high-risk medulloblastoma in patients over 3 years of age: carboplatin, cisplatin, cyclophosphamide, lomustine, temozolomide, thiotepa, vincristine

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:The University Of Birmingham
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.